Trial Profile
A phase I/IIa single and multiple ascending dose study for management of intractable pain in oncology patients
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Oct 2017
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary) ; Tetrahydrocannabinol (Primary)
- Indications Pain
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2017 Status changed from planning to not yet recruiting. as reported in an Aphria media release
- 24 Oct 2017 According to an Aphria media release, this trial will commence at Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney and will be supervised by Professor Stephen Clarke OAM.
- 14 Sep 2016 New trial record